• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Mercator MedSystems touts data for Bullfrog micro-infusion device

February 8, 2017 By Sarah Faulkner

Mercator MedSystems touts data for Bullfrog micro-infusion deviceMercator MedSystems touted data today from its Dance clinical trial evaluating the company’s Bullfrog micro-infusion device as a delivery system for a generic anti-inflammatory steroid, dexamethasome. Mercator’s results were presented at the International Symposium on Endovascular Therapy and Leipzig Interventional Course.

The steroid was delivered to tissues around femoropopliteal arteries after patients underwent endovascular intervention to forcibly open obstructions, the Emeryville, Calif.-based company said.

The Bullfrog micro-infusion device is FDA 510(k)-cleared and CE-Marked. It was designed to deliver therapeutic and diagnostic agents directly and non-systemically through blood vessel walls into adventitial tissues. The device is tipped with a balloon-sheathed microneedle, which can target vessels 2 to 8 millimeters in diameter.

The 13-month data from the clinical trial were separated int0 2 groups, based upon the method of revascularization – artherectomy or angioplasty without artherectomy.

Both groups experienced no post-operative deaths within 30 days. Major adverse limb events prior to revascularization was reported as 1.6% in the atherectomy group and 0.9% in the angioplasty group.

Primary patency, defined as the lack of clinically-driven target lesion revascularization, was 88.7% for the atherectomy group and 89.1% in the angioplasty group at 13 months.

“We attribute the success seen in the DANCE trial to the Bullfrog device and its ability to efficiently deliver drug in difficult-to-reach anatomy,” co-principal investigator Dr. Mahmood Razavi said in prepared remarks. “Technologies such as drug-coated balloons or drug-eluting stents use chemotherapeutic agents to reduce the risk of scar tissue buildup inside the arteries. Alternatively, we have proposed that the delivery of an anti-inflammatory agent to the outside of the artery enhances the healing process and interrupts the cascade leading to scar formation and restenosis. Overall, we have found the therapy in DANCE to be intuitive, safe and effective.”

“The successful outcomes from the DANCE trial validate the efficient and precise capability of a micro-infusion approach using the Bullfrog device,” Mercator CEO Trent Reutiman added. “We believe that this represents the first of many potential applications utilizing the Bullfrog for targeted drug delivery with direct visualization.”

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Vascular, Wall Street Beat Tagged With: Mercator MedSystems

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS